Literature DB >> 21859247

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.

Paolo Anderlini, Rima M Saliba, Celina Ledesma, Christina Chancoco, Amin M Alousi, Elizabeth J Shpall, Uday R Popat, Chitra M Hosing, Issa F Khouri, Yago Nieto, Stefan Ciurea, Anas Younes, Michelle A Fanale, Sandra Acholonu, Rosamar Valverde, Richard E Champlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21859247      PMCID： PMC4245073          DOI： 10.3109/10428194.2011.615427

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

Authors:  Karl S Peggs; Ann Hunter; Rajesh Chopra; Anne Parker; Premini Mahendra; Donald Milligan; Charles Craddock; Ruth Pettengell; Ahmet Dogan; Kirsty J Thomson; Emma C Morris; Geoff Hale; Herman Waldmann; Anthony H Goldstone; David C Linch; Stephen Mackinnon
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

2.  Questions about gemcitabine dose rate: answered or unanswered?

Authors:  Varsha Gandhi
Journal:  J Clin Oncol       Date:  2007-12-20       Impact factor: 44.544

Review 3.  Allogeneic transplantation for Hodgkin lymphoma.

Authors:  Karl S Peggs; Paolo Anderlini; Anna Sureda
Journal:  Br J Haematol       Date:  2008-08-15       Impact factor: 6.998

4.  Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

Authors:  Ryan H Shanks; David A Rizzieri; James L Flowers; O Michael Colvin; David J Adams
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

5.  Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.

Authors:  A Santoro; H Bredenfeld; L Devizzi; H Tesch; V Bonfante; S Viviani; F Fiedler; H S Parra; C Benoehr; M Pacini; G Bonadonna; V Diehl
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

Review 6.  Current role of gemcitabine in the treatment of Hodgkin lymphoma.

Authors:  Yasuhiro Oki; Anas Younes
Journal:  Leuk Lymphoma       Date:  2008-05

7.  Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.

Authors:  David A Rizzieri; Valerie K Ibom; Joseph O Moore; Carlos M DeCastro; Gary L Rosner; David J Adams; Traci Foster; Nancy Payne; Maria Thompson; James J Vredenburgh; Christina Gasparetto; Gwynn D Long; Nelson J Chao; Jon P Gockerman
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

8.  Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.

Authors:  Jonathan W Friedberg; Donna Neuberg; Helen Kim; Sarah Miyata; Mary McCauley; David C Fisher; Tak Takvorian; George P Canellos
Journal:  Cancer       Date:  2003-09-01       Impact factor: 6.860

9.  Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.

Authors:  Marcos de Lima; Athanasios Anagnostopoulos; Mark Munsell; Munir Shahjahan; Naoto Ueno; Cindy Ippoliti; Borje S Andersson; James Gajewski; Daniel Couriel; Jorge Cortes; Michele Donato; Joyce Neumann; Richard Champlin; Sergio Giralt
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

10.  Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: a Japanese survey.

Authors:  Y Kanda; Y Omuro; E Baba; K Oshima; K Nagafuji; Y Heike; Y Takaue; T Sasaki; H Sakamaki; M Harada
Journal:  Bone Marrow Transplant       Date:  2008-04-07       Impact factor: 5.483
View more
  2 in total

Review 1.  Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.

Authors:  A Rashidi; M Ebadi; A F Cashen
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

2.  Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.

Authors:  Benigno C Valdez; Guiyun Wang; David Murray; Yago Nieto; Yang Li; Jatin Shah; Francesco Turturro; Michael Wang; Donna M Weber; Richard E Champlin; Muzaffar H Qazilbash; Borje S Andersson
Journal:  Exp Hematol       Date:  2013-05-03       Impact factor: 3.084
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.